drugset / Trial / NCT04417049

Treatment of Bipolar Depression With Pentoxifylline

NCT04417049

Phase 0 Completed 6 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelTreatment

Summary

Growing theoretical and clinical evidence has suggested that pentoxifylline may have an effect in improving depressive symptoms. Herein, we aim to evaluate the effect of pentoxifylline in patients with bipolar depression over an 8-week trial.

Timeline

Start
2021-07-12
Primary completion
2021-11-03
Completion
2021-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 400 mg Oral

Indications